Children who received their 2- and 4-month-old doses of routine childhood vaccines late were most likely to have received no ...

This makes Pfizer a potentially cheap stock to buy while collecting a solid dividend. It's generated about $14 billion in ...

Calling it the “Health Care Medical Freedom Act,” a House Republican on Dec. 28 filed a bill that says health-care providers ...

A House Republican has filed a bill that says health-care providers could not “discriminate” against patients based on ...

Lifordi Immunotherapeutics and other biotechnology companies are using antibodies to precisely target drugs in the body.

Clinical data presented at ASCO 2025 showed an objective response rate (ORR) of 63% among all patients, with a median progression-free survival (PFS) of 7.7 months. Responses were seen across ...

Adding another potential wrinkle to the industry’s work with China is the Biosecure Act, a piece of China-targeting national ...

Calling it the “Health Care Medical Freedom Act,” a House Republican on Monday filed a bill that says health-care providers ...

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click for this updated look at PFE stock.

Calling it the “Health Care Medical Freedom Act,” a House Republican on Monday filed a bill that says health-care providers ...

The new bill, called the "Health Care Medical Freedom Act," would, in part, prohibit Florida providers from refusing to see ...

remove-circle Internet Archive's in-browser bookreader "theater" requires JavaScript to be enabled. It appears your browser does not have it turned on. Please see ...